Level 01 · The Gut Environment
Gut Dysbiosis — Disrupted Microbial Balance and the Estrobolome
The estrobolome is the collection of gut bacteria whose metabolic activity governs oestrogen recycling. In a healthy, diverse microbiome, estrobolome bacteria are present in low numbers and their beta-glucuronidase activity is kept in check by competing bacterial populations. Dysbiosis — overgrowth of pathogenic bacteria, reduced diversity, SIBO, or candida — disrupts this balance. The competing bacteria that suppress beta-glucuronidase-producing species are reduced. The producers proliferate.
The Estrobolome Concept
Specific bacterial genera including Clostridium, Bacteroides, Escherichia, and Firmicutes species produce beta-glucuronidase. Lactobacillus and Bifidobacterium populations suppress it. When dysbiosis reduces Lactobacillus and allows Clostridiales overgrowth, beta-glucuronidase activity rises — and the oestrogen recycling cycle begins.
Dysbiosis raises beta-glucuronidase activity
Level 02 · The Enzyme Problem
Elevated Beta-Glucuronidase — The Enzyme That Undoes the Liver's Work
The liver conjugates oestrogen metabolites — attaches glucuronic acid to them — as part of Phase 2 detoxification. This conjugation makes the oestrogen metabolites water-soluble and packages them for excretion in bile and stool. Beta-glucuronidase is the enzyme that cleaves that glucuronic acid bond, deconjugating the oestrogen metabolites back into their active, lipid-soluble form. This happens in the colon, where the deconjugated oestrogens are reabsorbed through the intestinal wall and re-enter circulation — despite the liver having already processed them for elimination. The liver's detoxification work is literally being undone in the gut.
Deconjugated oestrogens reabsorbed through colon wall
Level 03 · The Recycling Loop
Enterohepatic Recirculation — Oestrogen Returns to Circulation
Deconjugated oestrogen metabolites enter the portal circulation and return to the liver. The liver conjugates them again. They are excreted into bile again. They travel through the small intestine into the colon again. If beta-glucuronidase levels remain elevated, they are deconjugated and reabsorbed again. This is the enterohepatic recirculation loop — and in a dysbiotic gut, it creates a persistent oestrogen recycling cycle that operates independently of ovarian production. A woman in perimenopause with falling ovarian oestrogen output can simultaneously have elevated circulating oestrogen metabolites driven entirely by this gut mechanism.
This is a self-perpetuating cycle. The recycled oestrogen metabolites circulate, are processed by the liver, return to the gut, and are recycled again — as long as beta-glucuronidase remains elevated. Treating the hormonal symptoms without addressing the gut mechanism treats the downstream effect, not the driver.
Liver burden increases · Phase 2 detox capacity strained
Level 04 · The Liver Burden
Impaired Phase 2 Conjugation and the Oestrogen Metabolite Pathway Problem
The liver is now processing oestrogen metabolites repeatedly — conjugating the same molecules again and again. This increases the metabolic demand on Phase 2 liver detoxification, particularly the glucuronidation, sulfation, and methylation pathways. If methylation is impaired (MTHFR variants, B12 or folate deficiency), the 4-OH oestrogen pathway — the pathway associated with DNA-damaging quinone formation — is not cleared efficiently. The 2-OH:16-OH ratio shifts unfavourably. The oestrogen metabolite picture seen on the DUTCH deteriorates not because of excess oestrogen production but because of impaired processing and gut-driven recirculation.
Elevated circulating oestrogen metabolites despite normal or low serum oestradiol
Level 05 · The Clinical Picture
Oestrogen Dominance — Symptoms Present Regardless of Ovarian Output
The consequence is a clinical picture of oestrogen dominance — excess oestrogenic activity relative to progesterone — that is driven by recirculating metabolites rather than primary overproduction. Serum oestradiol may be normal or even low. The standard blood oestrogen test shows nothing. The DUTCH shows the metabolite burden. The GI-MAP shows the beta-glucuronidase that is driving it. Without both tests, the mechanism is invisible.
Level 06 · Clinical Presentations of Oestrogen Dominance
The Downstream Symptoms — All Potentially Driven by a Gut Mechanism
Menstrual
Heavy periods, clotting, shortened cycles, breast tenderness pre-menstrually, PMS
Weight and Body Composition
Hip and thigh fat accumulation, difficulty losing weight despite diet, fluid retention
Mood and Cognitive
Anxiety, mood instability, brain fog, poor sleep — oestrogen excess disrupts GABA and progesterone balance
Proliferative Risk
Fibrocystic breasts, uterine fibroids, endometriosis — all oestrogen-dependent tissue proliferation conditions
Thyroid Interference
Elevated oestrogen raises SHBG and thyroid binding globulin, reducing free thyroid hormone availability — hypothyroid symptoms despite normal TSH
Invisible on Blood Test
Serum oestradiol normal or low. The mechanism only shows on GI-MAP (beta-glucuronidase) + DUTCH (metabolite pathways)
Why this matters clinically
A woman presenting with heavy periods, breast tenderness, mood instability, and difficulty losing weight — all classic oestrogen dominance symptoms — will have a serum oestradiol result that shows nothing abnormal. Her GP has no mechanism to explain the symptoms. The functional medicine picture shows elevated GI-MAP beta-glucuronidase driving oestrogen recirculation, a DUTCH with unfavourable metabolite ratios, and potentially MTHFR-impaired methylation reducing clearance. The treatment is gut-first: reduce dysbiosis, support Lactobacillus and Bifidobacterium, use calcium-D-glucarate to inhibit beta-glucuronidase, and support methylation with appropriate B vitamins. Hormonal interventions without this groundwork produce incomplete and temporary results.
The Two Tests That Make This Cascade Visible
GI-MAP
Beta-glucuronidase · Dysbiosis markers · Candida · SIBO indicators · Lactobacillus and Bifidobacterium levels
DUTCH Plus
2-OH:16-OH ratio · 4-OH methylation markers · Oestrogen metabolite pathways · Phase 2 conjugation efficiency
Blood Chemistry
Homocysteine (methylation) · Serum oestradiol · SHBG · Liver enzymes (GGT, ALT) · Thyroid panel
MTHFR / OAT
MTHFR variant status · OAT methylation markers · B12 functional status · Folate cycle intermediates
GI-MAP beta-glucuronidase and DUTCH oestrogen metabolites — together
The RGS programme addresses the gut mechanism. The DUTCH Plus assessment reveals the metabolite picture. Both together give you the full gut-hormone cascade — and the clinical protocol to address it at the right level.